Gumińska, M.; Goś, R.; Śmigielski, J.; Nowak, M.S. Topical Treatment of Elevated Intraocular Pressure in Patients with Graves’ Orbitopathy. Int. J. Environ. Res. Public Health2020, 17, 9331.
Gumińska, M.; Goś, R.; Śmigielski, J.; Nowak, M.S. Topical Treatment of Elevated Intraocular Pressure in Patients with Graves’ Orbitopathy. Int. J. Environ. Res. Public Health 2020, 17, 9331.
Gumińska, M.; Goś, R.; Śmigielski, J.; Nowak, M.S. Topical Treatment of Elevated Intraocular Pressure in Patients with Graves’ Orbitopathy. Int. J. Environ. Res. Public Health2020, 17, 9331.
Gumińska, M.; Goś, R.; Śmigielski, J.; Nowak, M.S. Topical Treatment of Elevated Intraocular Pressure in Patients with Graves’ Orbitopathy. Int. J. Environ. Res. Public Health 2020, 17, 9331.
Abstract
Purpose: The evaluation of the efficacy of topical hypotensive treatment and/or systemic corticosteroids therapy in patients with elevated intraocular pressure and Graves’ orbitopathy (GO). Methods: 172 eyes in 86 individuals with duration of GO ≥ 3 months, intraocular pressure in either eye ≥ 25.0 mmHg and GO ranked ≥ 3 at least in one eye in modified CAS form, were included. The study subjects were divided into three treatment subgroups: subgroup I was administered latanoprost QD; subgroup II was administered a combined preparation of brimonidine and timolol BID; subgroup III was the control group, not receiving any topical hypotensive treatment. All the study participants received systemic treatment – intravenous corticosteroid therapy at the same dose, according to the EUGOGO guideline Results: On the final visit, the mean IOP value was significantly lower in all treatment subgroups comparing to the initial values. In both subgroups receiving topical treatment the IOP reduction was higher than in the control group receiving systemic corticosteroids only. However, the latanoprost eye drops decreased intraocular pressure more effectively than drops containing brimonidine and timolol. Conclusion: Topical ocular hypotensive treatment is effective in reducing intraocular pressure in GO and decreases intraocular pressure more effectively than systemic corticosteroid therapy alone.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
